

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dectomax 5 mg/ml pour-on solution for cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Doramectin 5.0 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Trolamine (as an antioxidant)	0.5 mg
Cetearyl octanoate	
Isopropyl alcohol	

Clear, colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Cattle.

3.2 Indications for use for each target species

For treatment of infestations of gastrointestinal roundworms, lungworms, eyeworms, warbles, sucking and biting lice, mange mites and hornfly in cattle.

Gastrointestinal roundworms (adults and fourth stage larvae)

Ostertagia ostertagi (inc. inhibited larvae)

*O. lyrata*¹

Haemonchus placei

Trichostrongylus axei

T. colubriformis

Cooperia oncophora

*C. punctata*¹

*C. surnabada*¹ (syn. *mcmasteri*)

*Bunostomum phlebotomum*¹

Oesophagostomum radiatum

Trichuris spp¹

¹ adults

Lungworms (adults and fourth stage larvae)

Dictyocaulus viviparus

Eyeworms (adults)

Thelazia spp

Warbles (parasitic stages)
Hypoderma bovis, *H. lineatum*

Biting lice
Damalinia (Bovicola) bovis

Sucking lice
Haematopinus eurysternus,
Linognathus vituli,
Solenopotes capillatus

Mange mites
Psoroptes bovis,
Sarcoptes scabiei,
Chorioptes bovis

Horn fly
Haematobia irritans

Duration of activity

Following veterinary medicinal product administration, efficacy against re-infection with the following parasites persists for the period indicated:

Species	Days
<i>Ostertagia ostertagi</i>	35
<i>Cooperia oncophora</i>	28
<i>Dictyocaulus viviparus</i>	42
<i>Linognathis vituli</i>	49
<i>Oesophagostomum radiatum</i>	21
<i>Damalinia (Bovicola) bovis</i>	42
<i>Trichostrongylus axei</i>	28
<i>Solenopotes capillatus</i>	35

The veterinary medicinal product also controls horn flies (*Haematobia irritans*) for at least 42 days after treatment.

3.3 Contraindications

The veterinary medicinal product has been formulated for topical application specifically for cattle. It should not be administered to other species as severe adverse reactions, including fatalities in dogs, may occur.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

See section 3.5 "Other precautions".

3.4 Special warnings

For external use only.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- under dosing, which may be due to underestimation of bodyweight, misadministration of the veterinary medicinal product, or lack of calibration of a dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. faecal egg count reduction test). Where the results of the test(s) strongly suggest resistance

to a particular anthelmintic, an anthelmintic belonging to a different pharmacological class and having a different mode of action should be used.

Do not apply to areas of skin that are contaminated with mud or manure.

Therapeutic efficacy for internal and external parasites is not affected by heavy rainfall (2 cm in 1 hour) either before (20 minutes) or after (20 and 40 minutes) treatment. The influence of extreme weather conditions on efficacy is unknown.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Persons with known hypersensitivity to the active substance should avoid contact with the veterinary medicinal product. Do not smoke or eat while handling the veterinary medicinal product. Wash hands after use. The veterinary medicinal product may be irritating to human skin and eyes and users should be careful not to apply it to themselves or to other persons. Personal protective equipment consisting of rubber gloves and boots with a waterproof coat should be worn when handling the veterinary medicinal product. Protective clothing should be washed after use. If accidental skin contact occurs, wash the affected area immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and get medical attention. Use only in well ventilated areas or outdoors.

Highly Flammable - Keep away from heat, sparks, open flame or other sources of ignition.

Special precautions for the protection of the environment:

Doramectin is very toxic to dung fauna and aquatic organisms and may accumulate in sediments.

The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of doramectin (and veterinary medicinal products of the same anthelmintic class) in cattle.

The risk to aquatic ecosystems will be reduced by keeping treated cattle away from water bodies for two to five weeks after treatment.

Other precautions:

Avermectins may not be well tolerated in all non-target species. Cases of intolerance with fatal outcome are reported in dogs, especially Collies, old English Sheepdogs and related breeds or crosses, and also in turtles/tortoise. Care should be taken to avoid ingestion of spilled veterinary medicinal product or access to containers by these other species.

To avoid secondary reactions due to death of Hypoderma larvae in the oesophagus or the spine, it is recommended to administer the veterinary medicinal product at the end of the period of warble fly activity and before the larvae reach their resting sites. Consult your veterinary surgeon on the correct timing of treatment.

3.6 Adverse events

Cattle:

Rare (1 to 10 animals / 10,000 animals treated):	Application site lesion ¹
---	--------------------------------------

¹ Small

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Do not use in non-lactating dairy cows, including pregnant heifers, within 60 days prior to calving.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

3.9 Administration routes and dosage

Pour-on use.

A single treatment of 1 ml (5 mg doramectin) per 10 kg bodyweight, equivalent to 500 µg/kg bodyweight, applied topically along the mid-line of the back in a narrow strip between the withers and tail head.

To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked.

If animals are to be treated collectively rather than individually, they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- and over- dosing.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdoses up to 5 times the label recommended dose resulted in no clinical signs that could be attributed to treatment with doramectin.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: 35 days.

Not authorised for use in animals producing milk for human consumption.

Do not use in pregnant cows or heifers which are intended to produce milk for human consumption within 2 months of expected parturition.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP 54AA03

4.2 Pharmacodynamics

Doramectin is a fermentation-derived antiparasitic agent, which belongs to the avermectin class, and is closely related structurally to ivermectin. Both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods. Whilst it is not possible to assign a single mode of action to the avermectins, it is likely that the entire series share a common

mechanism. In parasitic organisms the effect is mediated through a specific avermectin-binding site. The physiological response to avermectin binding is an increase in membrane permeability to chloride ions. In invertebrate nervous tissue an influx of chloride ions into the excitatory motor neurone in nematodes or muscle cell of arthropods results in hyperpolarisation and the elimination of signal transmission with resulting paralysis.

4.3 Pharmacokinetics

Maximum plasma concentration of doramectin occurs in cattle approximately 9 days after topical administration of the veterinary medicinal product. An (apparent) elimination half-life of around 10 days results in sustained doramectin concentrations, which protect animals from parasitic infection and re-infection for extended periods following treatment.

Environmental properties

Like other macrocyclic lactones, doramectin has the potential to adversely affect non-target organisms. Following treatment, excretion of potentially toxic levels of doramectin may take place over a period of several weeks. Faeces containing doramectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation.

Doramectin is very toxic to aquatic organisms and may accumulate in sediments.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 4 years

Shelf life after first opening the immediate packaging: 1 year

5.3 Special precautions for storage

Store below 30 °C.

5.4 Nature and composition of immediate packaging

The veterinary medicinal product will be supplied in:

- 250 ml and 1 L multi-dose high-density polyethylene bottles with screw-top lids and dosing cups in a carton box, and
- 2.5 L, 3 L and 5 L multi-dose high-density polyethylene bottles with screw-top lids and draw-off adaptor in a carton box.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or used container.

The veterinary medicinal product should not enter water courses as doramectin is extremely dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium S.A

7. MARKETING AUTHORISATION NUMBER(S)

VPA10387/020/001

8. DATE OF FIRST AUTHORISATION

09/12/2013

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

12/12/2023

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).